Loading...
Loading...
AZYO| Name | Value |
|---|---|
| Revenues | 12.6M |
| Cost of Revenue | 7.7M |
| Gross Profit | 4.9M |
| Operating Expense | 13.1M |
| Operating I/L | -8.2M |
| Other Income/Expense | -1.2M |
| Interest Income | 0.0M |
| Pretax | -9.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -9.4M |
Aziyo Biologics, Inc. is a regenerative medicine company specializing in developing products for the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. Its offerings include CanGaroo, a product designed to reduce infection risk post-surgical implantation of electronic devices, as well as cardiovascular products like ProxiCor, Tyke, and VasCure for tissue repairs and peripheral vasculature reconstruction. The company also provides human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V, along with SimpliDerm for integumental tissue repair. Additionally, it offers contract manufacturing services for various products to corporate customers.
